Financial Data and Key Metrics Changes - The company reported consolidated revenues of $525 million for Q2 2020, a decrease of 19.8% year-over-year [10][34] - Non-GAAP earnings per share were $1.51, with an average of 49.6 million shares outstanding [36] - Consolidated gross margin decreased to 65.8% from 67.3% year-over-year, primarily impacted by April's performance [34] - Free cash flow was negative $63.5 million, driven by lower customer collections and a buildup of inventory [37] Business Line Data and Key Metrics Changes - CooperVision revenues were $402 million, down 15%, while CooperSurgical revenues were $123 million, down 27% [10] - CooperVision's regional revenue declined: Americas down 22%, EMEA down 11%, and Asia-Pac down 10% [11] - MiSight revenue grew 52% to $1.4 million, indicating strong interest from optometrists [21] Market Data and Key Metrics Changes - The Americas market saw a significant decline in new fits, which typically account for about 15% of revenues [14][50] - In April, sales were down roughly 45%, with a gradual recovery noted in May and June [13][16] - The company expects CooperVision's fiscal Q3 sales to decline by 15% to 20% year-over-year [17] Company Strategy and Development Direction - The company is focused on long-term objectives, including product development, increasing manufacturing output, and enhancing distribution capabilities [8] - New product launches, such as Biofinity toric multifocal and extended toric range for Clariti, are part of the strategy to capture market share [18] - The company is committed to maintaining employee compensation and support during the pandemic [7] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about recovery trends as economies reopen, particularly in regions like China [16][17] - The company anticipates a focus on daily silicone hydrogels due to hygiene concerns post-COVID [44][52] - Management is cautious about forecasting but expects gradual improvement in sales as optometry offices reopen [17][40] Other Important Information - The company repurchased approximately 161,000 shares for $47.8 million during the quarter [38] - Net debt increased by $118.6 million to $1.8 billion, with an adjusted leverage ratio of 2.18 times [37] - The company has not curtailed investments in key products, maintaining a focus on R&D despite the pandemic [35] Q&A Session Summary Question: Impact of COVID-19 on CooperVision's product mix - Management noted that daily silicone hydrogel products performed better during the downturn, while legacy products faced significant declines [43][44] Question: Geographic recovery trends - Management indicated that Asia-Pac is showing signs of growth, while the Americas are lagging behind [56][58] Question: Future sales expectations for fiscal Q4 - Management is optimistic about returning to flat or slight growth in CooperVision for Q4, depending on the reopening of stores and channel inventory recovery [63][64]

| --- | --- | --- | --- | |---------------|-------|-------|-------| | | | | | | | | | | | Investor | | | | | | | | | | Presentation | | | | | | | | | | | | | | | | | | | | MARCH 5, 2020 | | | | | | | | | | | | | | | | | | | CooperVision® ®COPYRIGHT 2019 COOPERCOMPANIES Forward Looking Statements This earnings release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, e ...

Financial Performance - Gross profit for the first quarter of fiscal 2020 was $426.5 million, a 2% increase from $418.5 million in the prior year period[148] - Operating income remained relatively flat at $111.1 million compared to $110.9 million in the prior year period[148] - Diluted earnings per share decreased by 12% to $1.82 from $2.07 in the prior year period, primarily due to tax benefits in the previous year[148] - Cash provided by operations increased to $129.7 million from $101.8 million in the prior year period[148] - Net sales increased by 3% compared to the same period in 2019[163] - CooperVision's net sales for the three months ended January 31, 2020, were $485.2 million, representing a 3% increase from $470.1 million in the same period of 2019[164] - CooperSurgical's net sales increased by 2% to $161.0 million, with office and surgical products growing by 3% to $98.5 million[175] - Operating income for CooperVision increased by 6% to $122.9 million, while CooperSurgical's operating income decreased by 76% to $1.7 million[190] Cost and Expenses - Cost of sales as a percentage of net sales increased to 34% from 33% in the prior year[163] - Gross margin for CooperVision decreased to 65% in Q1 2020 from 66% in Q1 2019, primarily due to increased manufacturing costs[180] - Selling, General and Administrative expenses for CooperVision rose by 2% to $172.4 million, maintaining 36% of net sales[182] - Research and Development expenses for CooperVision decreased by 3% to $13.1 million, remaining at 3% of net sales[186] - CooperSurgical's R&D expenses increased by 25% to $9.1 million, driven by investments in new product development[187] - Total share-based compensation expense decreased to $10.3 million in Q1 2020 from $11.7 million in Q1 2019[196] Cash Flow and Investments - Operating cash flow increased to $129.7 million in Q1 2020, up from $101.8 million in Q1 2019, representing a 27.5% increase[198] - Free cash flow reached $60.7 million, a significant increase of 169% compared to the prior year period[198] - Cash used in investing activities decreased to $78.4 million in Q1 2020 from $129.2 million in Q1 2019, largely due to lower acquisition payments[206] - Cash flows from financing activities resulted in a $63.2 million outflow in Q1 2020, compared to a $93.2 million inflow in Q1 2019[207] Debt and Liquidity - The company had $76.8 million in unrestricted cash and $763.8 million available under its revolving credit facility as of January 31, 2020[157] - Total debt decreased to $1,776.7 million from $1,826.3 million, resulting in a debt-to-equity ratio of 0.48:1, down from 0.50:1[199] - The Company has $500 million outstanding under the 2019 Term Loan Agreement, which was extended to September 25, 2020[222] - As of January 31, 2020, the Company had $1.0 billion outstanding under the 2017 Term Loan Agreement, which was part of the funding for the PARAGARD acquisition[223] - The 2016 Credit Agreement includes a multi-currency revolving credit facility of $1.0 billion and a term loan facility of $830 million, maturing on March 1, 2021[224] - At January 31, 2020, the Company had $235 million outstanding under the 2016 Revolving Credit Facility, with $763.8 million available[224] - A 1% increase or decrease in interest rates would result in a quarterly interest expense change of approximately $4.6 million based on average debt outstanding for Q1 fiscal 2020[225] Inventory and Receivables - Inventory months on hand increased to 7.2 at January 31, 2020, compared to 6.4 at October 31, 2019, indicating a rise in finished goods and raw materials[201] - Days sales outstanding (DSO) increased to 60 days in Q1 2020 from 56 days in Q1 2019, attributed to increased revenue and timing of collections[201] Regulatory and Product Developments - CooperVision received FDA approval for MiSight® 1 day lens, the first product indicated to slow myopia progression in children[152] - CooperSurgical acquired a privately-held distributor of IVF medical devices on December 13, 2019, enhancing its product offerings[156] Foreign Exchange and Risk Management - Foreign exchange rates negatively impacted sales by approximately $2.1 million in Q1 2020, but net sales increased by 4% in constant currency[168] - The Company is exposed to foreign exchange risks primarily from currencies such as British pound sterling, euro, and Japanese yen[221] - The Company did not have any derivative assets or liabilities related to interest rate swaps or foreign currency contracts as of January 31, 2020[221] - The Company may hedge a portion of variable rate debt to mitigate interest rate risk[221]

The Cooper Companies, Inc. (NASDAQ:COO) Q1 2020 Earnings Conference Call March 5, 2020 5:00 PM ET Company Participants Kim Duncan – Vice President-Investor Relations and Administrations Al White – President and Chief Executive Officer Brian Andrews – Chief Financial Officer and Treasurer Conference Call Participants Larry Keusch – Raymond James Jeff Johnson – Baird Anthony Petrone – Jefferies Larry Biegelsen – Wells Fargo Matthew Mishan – KeyBanc Chris Cooley – Stephens Jon Block – Stifel Matthew O'Brien – ...

| --- | --- | --- | --- | |------------------|-------|-------|-------| | | | | | | | | | | | Investor | | | | | | | | | | | | | | | Presentation | | | | | | | | | | | | | | | | | | | | JANUARY 14, 2020 | | | | | | | | | | | | | | | | | | | CooperVision® ®COPYRIGHT 2019 COOPERCOMPANIES Forward Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, futur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________ FORM 10-K ________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED OCTOBER 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-08597 ________________________ THE COOPER COMPANIES, INC. (Exact name of registrant as specified in i ...

The Cooper Companies, Inc. (NASDAQ:COO) Q4 2019 Results Conference Call December 5, 2019 5:00 PM ET Company Participants Kim Duncan - Vice President, Investor Relations & Administration Al White - President & Chief Executive Officer Brian Andrews - Chief Financial Officer & Treasurer Conference Call Participants Jason Bednar - Baird Larry Biegelsen - Wells Fargo Larry Keusch - Raymond James Anthony Petrone - Jefferies Matthew Mishan - KeyBanc Matthew O'Brien - Piper Jaffray Jon Block - Stifel Chris Cooley - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________ FORM 10-Q _____________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For Quarterly Period Ended July 31, 2019 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 1-8597 ____________________ ...

The Cooper Companies, Inc. (NASDAQ:COO) Q3 2019 Earnings Conference Call August 29, 2019 5:00 PM ET Company Participants Kim Duncan - Vice President, Investor Relations & Administration Al White - President & Chief Executive Officer Brian Andrews - Chief Financial Officer & Treasurer Conference Call Participants Larry Biegelsen - Wells Fargo Jeff Johnson - Baird Joanne Wuensch - BMO Capital Markets Matthew Mishan - KeyBanc Larry Keusch - Raymond James Chris Cooley - Stephens Anthony Petrone - Jefferies Robb ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________ FORM 10-Q _____________________________________________________________ ý Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For Quarterly Period Ended April 30, 2019 o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 1-8597 ___________________ ...